Cboe Global Markets, Inc. CBOE
377.36 USD +1.94 (+0.52%)
As ofNov 16, 2026, 9:38 AM EST
376.88 Day range 379.76
231.51 52-week range 377.64
- YTD
- +50.34%
- 1 year
- +46.07%
News
zacks.com CBOE Global (CBOE) is a Great Momentum Stock: Should You Buy? Does CBOE Global (CBOE) have what it takes to be a top stock pick for momentum investors? Let's find out.marketscreener.com PureTech Health plc Stock Oct. 25 Puretech Health plc and Gallop Oncology Present Phase 1B Results for Lyt-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia CI Oct. 19 PureTech Health…
briefs.co Kalshi's stock perps go live as traders chase AI hedges and leverage Kalshi began trading perpetual futures on 50 large stocks, drawing heavy volume in Nvidia, Micron and SpaceX with adjustable ...
moneyweb.co.za Traders turn to Kalshi stock ‘perps’ on Nvidia and SpaceX as leverage fears grow The perps have piqued the interest from both retail customers and hedge funds as an alternative to existing listed contracts.
kalkine.com.au Global X S&P 500 Covered Call Complex ETF (ASX:UYLD): How Covered Calls Trade US Equity Upside for Option Income Global X S&P 500 Covered Call Complex ETF (ASX:UYLD) combines a portfolio linked to large US companies with the sale of call Options on the S&P 500. The resulting premiums provide an additional…
markets.businessinsider.com AGF Investments Announces 2026 Estimated Annual Reinvested Capital Gains Distributions for ETFs AGF Investments Inc. (AGF Investments) today announced the estimated annual 2026 reinvested distributions for the AGF Investments ETFs listed on the Toronto Stock Exchange or Cboe Canada Inc. as set…
theglobeandmail.com AGF Investments Announces 2026 Estimated Annual Reinvested Capital Gains Distributions for ETFs AGF Investments Inc. (AGF Investments) today announced the estimated annual 2026 reinvested distributions for the AGF Investments ETFs listed on the Toronto Stock Exchange or Cboe Canada Inc. as set…
manilatimes.net Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points -7.6 point ...
